ClinicalTrials.gg
CompletedNCT02889809Updated Jan 17, 2024Results posted

Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year

A Phase 4 interventional study of Fluticasone furoate and Placebo in Asthma, sponsored by GlaxoSmithKline. Completed at 55 sites in 6 countries. Open to participants aged 5 Years to 9 Years. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
477
Allocation
Randomized
Ages
5 Years to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.

Enrollment
10th of 40
477 · median 102
Started
2017
with 1 other
Phase 4
6 of 40
none open now
Registered
31st of 40
by date
Lead sponsor
36 of 40
GlaxoSmithKline

Among the 40 studies testing fluticasone furoate in Asthma, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 4, and was the 31st registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing fluticasone furoate in Asthma as a file.
02

Study summary

There is a regulatory requirement to evaluate the extent of reduction (if any) of growth velocity associated with inhaled corticosteroid (ICS) containing products that are to be administered to children, and to this end there is Food and Drug Administration (FDA) regulatory guidance. This is a randomised, single-blind (run-in period)/double-blind (treatment period), parallel group, placebo controlled, multicentre study to assess the effect of once daily (OD) inhaled fluticasone furoate (FF) 50 microgram (mcg) on growth velocity in prepubertal asthmatic children on a background therapy of open-label montelukast. This study will be conducted over a total duration of approximately 76 weeks: 16-week run-in period (single-blind placebo inhaler), 52-week double-blind treatment period (inhaled FF 50 mcg /placebo administered OD in the morning for 52 weeks) and 8-week follow-up period. The purpose of the study is to evaluate the magnitude of effect (with a level of precision) on growth velocity of prepubertal asthmatic paediatric subjects (aged 5 to \<9 years) following administration of OD inhaled FF 50 mcg for one year. This study fulfills European Union (EU) and United States (US) regulatory requirements for the evaluation of potential growth suppression in children.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Growth Velocity
  • Prepubertal
  • Asthma
  • Paediatric
04

Who can participate

Ages eligible
5 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects.
  • Age: Males between 5 and \<9 years old; Females between 5 and \<8 years old.
  • Subjects must be pre-pubertal (Tanner Stage 1).
  • Height centile between 3% and 97% based on local growth charts.
  • Subjects with body weight and that is between 3rd and 97th centile based on the United State (US) Centres for Disease Control and Prevention (CDC) standard statistics or any local standards outside the US.
  • A documented history of symptoms consistent with a diagnosis of asthma for at least 6 months prior to Visit 1.
  • A pre-bronchodilatory forced expiratory flow in 1 second () at Visit 1 (Screening) of between >=60% to \<=95% predicted. There should be no short acting beta 2 agonist (SABA) use within 4 hours of this measurement.
  • Able to replace their current SABA treatment with study supplied rescue albuterol/salbutamol provided at Visit 1 for use as needed for the duration of the study.
  • A childhood asthma control test (cACT) score of >19.
  • Subjects should have required at least one course of for their asthma (inhaled or oral) in the past year.
  • There must be no ICS use within 6 weeks of Visit 1 (Screening).
  • There must be no oral corticosteroids use within 12 weeks of Visit 1 (Screening).
  • Using one or more of the following asthma therapies prior to entry into the study:

Short acting beta-agonist (SABA) inhaler alone (example given [e.g.] salbutamol) on an as needed basis and/or regular non-ICS controller medications for asthma (e.g. cromones or leukotriene receptor antagonists).

  • Written from at least one parent/care giver (legal guardian) and accompanying informed assent from the subject (where the subject is able to provide assent) prior to admission to the study. If applicable, subject must be able and willing to give assent to take part in the study according to local requirement. The study investigator is accountable for determining a child's capacity to assent for participation in a research study, taking into consideration any standards set by the responsible Independent Ethics Committee (IEC). Subject and their legal guardian(s) understand that they must comply with study medication administration regimens and study assessments including recording of symptom scores and rescue albuterol/salbutamol use, attending all study visits, and being accessible by telephone.

Exclusion criteria

Exclusion Criteria:

  • Growth Criteria: Any previous or current condition that affects growth, including sleep disorders, endocrine disorders, skeletal dysplasia, Turner and Noonan syndromes, Marfan, Beckwith-Wiedeman and Sotos syndromes, Klinefelter's syndrome, coeliac disease, inflammatory bowel diseases and renal failure or any significant abnormality or medical condition that is identified at the screening medical assessment (including serious psychological disorder) that is likely to interfere with the conduct of the study.
  • Subjects with premature adrenarche.
  • A child who is unable to stand, or who finds standing difficult due to illness or physical disabilities should be excluded.
  • Disease Criteria: Subjects with a history of asthma exacerbation requiring the use of systemic (tablets, suspension, or injection) for at least 3 days or use of a depot corticosteroid injection within 3 months or those requiring hospitalisation for asthma (within 6 months) prior to screening.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the Investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Clinical visual evidence of candidiasis at Visit 1 (Screening).
  • Any significant abnormality or medical condition identified at the screening medical assessment that in the Investigator's opinion, preclude entry into the study due to risk to the subject or that may interfere with the outcome of the study.
  • General: Prior use of any medication or treatment that might affect growth including, but not limited to: amphetamines, anticonvulsants, biphosphonates, calcitonin, calcitriol, erythropoietin, growth hormone, methylphenidate, phosphate binders, antithyroid drugs (e.g., Methimazole) or thyroid hormone.
  • Use of any of the prohibited medications listed in the study protocol.
  • : Known hypersensitivity to corticosteroids, leukotrienes, or any in the ELLIPTA (ELLIPTA is a Glaxosmithkline owned trademark for dry powder inhaler) inhaler and study tablets.
  • Milk Protein Allergy: History of severe milk protein allergy.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than 4 investigational medicinal products within 12 months prior to the first dosing day.
  • Children who are an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
  • The Parent or Guardian has a history of known or suspected psychiatric disease, intellectual deficiency, substance abuse or other condition (e.g. inability to read, comprehend or write) which may affect: validity of consent to participate in the study; adequate supervision of the subject during the study; compliance of subject with study medication and study procedures (e.g. completion of daily diary, attending scheduled clinic visits); subject safety and well-being.
  • Children in care: Children who are wards of the government or state are not eligible for participation in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
477 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate 50 mcg

    During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.

    Drug: Fluticasone furoate · Drug: Placebo · Drug: Montelukast · Drug: Short Acting Beta 2 Agonist

  • Placebo comparator
    Placebo

    During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams \[mg\] for subjects who are 5 years old and 5 mg for subjects who are \>=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol \[inhalation aerosol or nebuliser\]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.

    Drug: Placebo · Drug: Montelukast · Drug: Short Acting Beta 2 Agonist

Interventions

  • Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.

  • DrugPlacebo

    Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.

  • Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (\>=6 year old subjects)

  • DrugShort Acting Beta 2 Agonist

    Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.

06

What researchers measure

Primary outcomes

  1. Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry

    Three reproducible height measurements were taken using a stadiometer at each visit and were recorded to nearest 1/10th of centimeter. Each set of triplicate measurements was averaged to derive one estimated height per participant per visit. Growth velocity was calculated for each participant over double-blind treatment period (up to 52 weeks \[wk\]) by fitting a regression line to averaged height measurements at each visit for that participant during period. Slope of this regression line was participant's growth velocity for double-blind treatment period. Treatment policy estimand was assessed, including all on- and post-treatment data. Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16), 3(wk-8), and 5(wk0), data from at least two of these visits were used to fit a simple linear regression line against time and the slope of the fitted regression line was the participant's Baseline growth velocity.

    Time frame: Up to 52 weeks

Secondary outcomes

  1. Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period

    Three reproducible height measurements were taken using stadiometer at each visit\&were recorded to nearest 1/10th of a centimeter.Each set of triplicate measurements was averaged to derive one estimated height per participant per visit.Growth velocity(GV)was calculated for each participant over double-blind treatment(up to 52 weeks)period by fitting regression line to height measurements recorded for that participant during period.Each participant's double-blind(DB) treatment period GV was calculated based on all on \&off treatment height data \&was programmatically compared to data values from Standards from Birth to Maturity for Height,Weight,Height Velocity, established in British Children(1965)\&further updated for North American children(1985)using 3rd percentile value of age closest to participant's age at end of endpoint(i.e.either end of participant's DB treatment period \[Visit18 Wk 52\]/withdrawal from study\[Early Withdrawal Visit\]).Percentage values presented is rounded off.

    Time frame: Up to 52 weeks

  2. Percentage of Participants With Change in Growth Velocity Quartiles From Baseline to Endpoint

    Growth velocity(GV) quartile(defined as 1st quartile(1Q)=1st-25th percentile,2Q=26th-50th percentile,3Q=51st-75th percentile,4Q=76th-100th percentile) was determined at Baseline\&endpoint.Endpoint was defined as slope of simple linear regression of average stadiometric height recorded at week 28\& upto wk52.Baseline growth velocity was calculated as slope from simple linear regression of average stadiometric height recorded at wk-16,-8\&0.Baseline GV was programmatically compared to reference for standard height data using participant's estimated age at wk0\& age in reference data closest to actual age of participant to determine Baseline GV quartile.Endpoint GV was programmatically compared to reference data using participant's age at endpoint \& age in reference data that was closest to actual age of participant to determine endpoint GV quartile. Any increase/decrease indicates any increase/decrease in quartiles with reference to Baseline. Percentage values presented is rounded off.

    Time frame: Baseline and Endpoint (Week 28[Visit 12] up to and including Week 52 [Visit 18])

  3. Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period

    Growth velocity was calculated for each participant over double blind period by fitting regression line to height measurements recorded for that participant during period.Slope of this regression line was participant's growth velocity for double-blind treatment period.In order to be included in this analysis,participant must have data from Visit8(Wk 12) stadiometric height assessment.Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16),3(wk-8),\& 5(wk0),data from at least two of these visits were used to fit simple linear regression line against time\&slope of fitted regression line was participant's Baseline growth velocity.All available height data collected during double-blind treatment period upto Visit8(Wk12) while participant was on randomized double-blind treatment was considered.ANCOVA model was used to estimate mean treatment difference in growth velocity over 1st 12weeks of double-blind treatment period.

    Time frame: Up to 12 weeks (Visit 8) of double-blind treatment period

  4. Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint

    Each participant's SDS for each of three required stadiometric height measurements was calculated as:(observed height measurement-standard median height for age at Visit \[week-16\]) divided by (/) (\[standard 95th height percentile for age at visit-standard 5th height percentile for age at visit\]/\[2\*1.645\]).Standard median, 95th percentile, \& 5th percentile values were obtained from standard tables (Guidance for Industry Orally Inhaled \& Intranasal Corticosteroid). SDS for each height stadiometric measurement at each visit was calculated using percentiles from standard tables \& averaged for each participant before being summarized by treatment group. A reduction in SDS over time indicates growth deceleration \& an increase in SDS over time means growth acceleration.Baseline was defined as height SD score at Visit 5 (week 0). Endpoint was defined as height SD score at Visit 18 (week52) (on- \& off-treatment data). Change from Baseline was calculated as Endpoint value minus Baseline value.

    Time frame: Baseline (Week 0 [Visit 5]) and up to Endpoint (Week 52 [Visit 18])

  5. Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's judgement.

    Time frame: Up to 76 weeks

  6. Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period

    An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a single depot corticosteroid injection, or an in-patient hospitalization or emergency department (ED) visit due to asthma that required systemic corticosteroids. Number of participants with on-treatment asthma exacerbations during double-blind treatment period is presented.

    Time frame: Up to 52 weeks

07

Results

Posted Jan 4, 2022

Participant flow

This was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate (FF) 50 micrograms (mcg) once daily on growth velocity in prepubertal, pediatric participants with asthma.

Participant flow — Overall Study
MilestonePlaceboFF 50 mcg
Started239238
Completed196205
Not completed4333
Withdrew: Withdrawal by subject3021
Withdrew: Lost to follow-up11
Withdrew: Site closed1211

Outcome measures

PrimaryGrowth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry

Three reproducible height measurements were taken using a stadiometer at each visit and were recorded to nearest 1/10th of centimeter. Each set of triplicate measurements was averaged to derive one estimated height per participant per visit. Growth velocity was calculated for each participant over double-blind treatment period (up to 52 weeks \[wk\]) by fitting a regression line to averaged height measurements at each visit for that participant during period. Slope of this regression line was participant's growth velocity for double-blind treatment period. Treatment policy estimand was assessed, including all on- and post-treatment data. Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16), 3(wk-8), and 5(wk0), data from at least two of these visits were used to fit a simple linear regression line against time and the slope of the fitted regression line was the participant's Baseline growth velocity.

Time frame:
Up to 52 weeks
Reported as:
Least squares mean · Centimeter per year
Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry
Centimeter per yearPlaceboFF 50 mcg
Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry6.065 ± 0.10905.905 ± 0.1078
Statistical analysis
  • Placebo vs FF 50 mcg · Least square (ls) mean difference: -0.160 · 95% CI -0.462 to 0.142Analysis was performed using an analysis of covariance (ANCOVA) model adjusting for Baseline growth velocity, age at Visit 1, gender and country.
SecondaryPercentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period

Three reproducible height measurements were taken using stadiometer at each visit\&were recorded to nearest 1/10th of a centimeter.Each set of triplicate measurements was averaged to derive one estimated height per participant per visit.Growth velocity(GV)was calculated for each participant over double-blind treatment(up to 52 weeks)period by fitting regression line to height measurements recorded for that participant during period.Each participant's double-blind(DB) treatment period GV was calculated based on all on \&off treatment height data \&was programmatically compared to data values from Standards from Birth to Maturity for Height,Weight,Height Velocity, established in British Children(1965)\&further updated for North American children(1985)using 3rd percentile value of age closest to participant's age at end of endpoint(i.e.either end of participant's DB treatment period \[Visit18 Wk 52\]/withdrawal from study\[Early Withdrawal Visit\]).Percentage values presented is rounded off.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period
Percentage of participantsPlaceboFF 50 mcg
Percentage of Participants Below the Third Percentile of Growth Velocity During Double-blind Treatment Period97
SecondaryPercentage of Participants With Change in Growth Velocity Quartiles From Baseline to Endpoint

Growth velocity(GV) quartile(defined as 1st quartile(1Q)=1st-25th percentile,2Q=26th-50th percentile,3Q=51st-75th percentile,4Q=76th-100th percentile) was determined at Baseline\&endpoint.Endpoint was defined as slope of simple linear regression of average stadiometric height recorded at week 28\& upto wk52.Baseline growth velocity was calculated as slope from simple linear regression of average stadiometric height recorded at wk-16,-8\&0.Baseline GV was programmatically compared to reference for standard height data using participant's estimated age at wk0\& age in reference data closest to actual age of participant to determine Baseline GV quartile.Endpoint GV was programmatically compared to reference data using participant's age at endpoint \& age in reference data that was closest to actual age of participant to determine endpoint GV quartile. Any increase/decrease indicates any increase/decrease in quartiles with reference to Baseline. Percentage values presented is rounded off.

Time frame:
Baseline and Endpoint (Week 28[Visit 12] up to and including Week 52 [Visit 18])
Reported as:
Number · Percentage of Participants
Percentage of Participants With Change in Growth Velocity Quartiles From Baseline to Endpoint
Percentage of ParticipantsPlaceboFF 50 mcg
Any increase3332
Any decrease3438
SecondaryGrowth Velocity Over the First 12 Weeks of Double-blind Treatment Period

Growth velocity was calculated for each participant over double blind period by fitting regression line to height measurements recorded for that participant during period.Slope of this regression line was participant's growth velocity for double-blind treatment period.In order to be included in this analysis,participant must have data from Visit8(Wk 12) stadiometric height assessment.Baseline was included as covariate which was calculated based on stadiometric height measurements recorded at Visits 1(wk -16),3(wk-8),\& 5(wk0),data from at least two of these visits were used to fit simple linear regression line against time\&slope of fitted regression line was participant's Baseline growth velocity.All available height data collected during double-blind treatment period upto Visit8(Wk12) while participant was on randomized double-blind treatment was considered.ANCOVA model was used to estimate mean treatment difference in growth velocity over 1st 12weeks of double-blind treatment period.

Time frame:
Up to 12 weeks (Visit 8) of double-blind treatment period
Reported as:
Least squares mean · Centimeter per year
Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period
Centimeter per yearPlaceboFF 50 mcg
Growth Velocity Over the First 12 Weeks of Double-blind Treatment Period6.222 ± 0.18456.281 ± 0.1841
Statistical analysis
  • Placebo vs FF 50 mcg · Ls mean difference: 0.059 · 95% CI -0.455 to 0.572Analysis was performed using an ANCOVA model adjusting for Baseline growth velocity, age at Visit 1(wk -16), gender and country
SecondaryChange in Height Standard Deviation Scores (SDS) From Baseline to Endpoint

Each participant's SDS for each of three required stadiometric height measurements was calculated as:(observed height measurement-standard median height for age at Visit \[week-16\]) divided by (/) (\[standard 95th height percentile for age at visit-standard 5th height percentile for age at visit\]/\[2\*1.645\]).Standard median, 95th percentile, \& 5th percentile values were obtained from standard tables (Guidance for Industry Orally Inhaled \& Intranasal Corticosteroid). SDS for each height stadiometric measurement at each visit was calculated using percentiles from standard tables \& averaged for each participant before being summarized by treatment group. A reduction in SDS over time indicates growth deceleration \& an increase in SDS over time means growth acceleration.Baseline was defined as height SD score at Visit 5 (week 0). Endpoint was defined as height SD score at Visit 18 (week52) (on- \& off-treatment data). Change from Baseline was calculated as Endpoint value minus Baseline value.

Time frame:
Baseline (Week 0 [Visit 5]) and up to Endpoint (Week 52 [Visit 18])
Reported as:
Mean · Standard Deviation Score
Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint
Standard Deviation ScorePlaceboFF 50 mcg
Change in Height Standard Deviation Scores (SDS) From Baseline to Endpoint-0.02 ± 0.281-0.04 ± 0.281
SecondaryNumber of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's judgement.

Time frame:
Up to 76 weeks
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPlaceboFF 50 mcg
Any SAEs86
Any Non-serious AEs10599
SecondaryNumber of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period

An exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or a single depot corticosteroid injection, or an in-patient hospitalization or emergency department (ED) visit due to asthma that required systemic corticosteroids. Number of participants with on-treatment asthma exacerbations during double-blind treatment period is presented.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period
ParticipantsPlaceboFF 50 mcg
Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period227

Adverse events

Collected over All cause mortality, non-serious adverse events (AEs) and serious AEs were collected up to 76 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/239 (0%)8/239 (3.3%)105/239 (43.9%)
FF 50 mcg0/238 (0%)6/238 (2.5%)99/238 (41.6%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboFF 50 mcg
AsthmaRespiratory, thoracic and mediastinal disorders2/2390/238
FaecalomaGastrointestinal disorders0/2391/238
Adenoviral haemorrhagic cystitisInfections and infestations0/2391/238
AppendicitisInfections and infestations0/2391/238
BronchitisInfections and infestations0/2391/238
PneumoniaInfections and infestations1/2391/238
TonsillitisInfections and infestations0/2391/238
HaematuriaRenal and urinary disorders0/2391/238
Gastroenteritis norovirusInfections and infestations1/2390/238
Urinary tract infectionInfections and infestations1/2390/238
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboFF 50 mcg
Upper respiratory tract infectionInfections and infestations33/23929/238
NasopharyngitisInfections and infestations25/23923/238
PyrexiaGeneral disorders18/23913/238
RhinitisInfections and infestations18/23916/238
CoughRespiratory, thoracic and mediastinal disorders15/23912/238
BronchitisInfections and infestations12/2399/238
HeadacheNervous system disorders12/23910/238
InfluenzaInfections and infestations7/23911/238
Respiratory tract infection viralInfections and infestations4/23910/238
PharyngitisInfections and infestations9/2393/238

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFF 50 mcgTotal
Mean6.1 ± 1.076.3 ± 1.026.2 ± 1.05
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFF 50 mcgTotal
Female8494178
Male155144299
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboFF 50 mcgTotal
African American/African Heritage131326
Asian - Central/South Asian Heritage011
Multiple182038
White - Arabic/North African Heritage336
White - Mixed Race101
White - White/Caucasian/European Heritage204201405
08

Study locations

55 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Huntington Beach, California 92648, United States
  • GSK Investigational Site
    Homestead, Florida 33030, United States
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
  • GSK Investigational Site
    Miami, Florida 33134, United States
  • GSK Investigational Site
    Miami, Florida 33135, United States
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Miami, Florida 33175, United States
  • GSK Investigational Site
    Saint Petersburg, Florida 33710, United States
  • GSK Investigational Site
    Gainesville, Georgia 30501, United States
  • GSK Investigational Site
    Ypsilanti, Michigan 48197, United States
  • GSK Investigational Site
    Bellevue, Nebraska 68123, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118-2040, United States
  • GSK Investigational Site
    San Antonio, Texas 78230, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1122AAK, Argentina
  • GSK Investigational Site
    Lanús, Buenos Aires B1824KAJ, Argentina
  • GSK Investigational Site
    Buenos Aires, C1121ABE, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    Bialystok, 15-430, Poland
  • GSK Investigational Site
    Bialystok, 15879, Poland
  • GSK Investigational Site
    Bydgoszcz, 85-796, Poland
  • GSK Investigational Site
    Gdansk-Wrzeszcz, 80-405, Poland
  • GSK Investigational Site
    Krakow, 31-011, Poland
  • GSK Investigational Site
    Lublin, 20-093, Poland
  • GSK Investigational Site
    Skarzysko-Kamienna, 26-110, Poland
  • GSK Investigational Site
    Szczecin, 70-382, Poland
  • GSK Investigational Site
    Tarnow, 33-100, Poland
  • GSK Investigational Site
    Brasov, 500091, Romania
  • GSK Investigational Site
    Brasov, 500283, Romania
  • GSK Investigational Site
    Bucuresti, 020395, Romania
  • GSK Investigational Site
    ClujNapoca, 400001, Romania
  • GSK Investigational Site
    Sangiorgiu De Mures, 547530, Romania
  • GSK Investigational Site
    Moscow, 119991, Russian Federation
  • GSK Investigational Site
    Moscow, 129110, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630091, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 191025, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 192212, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 196191, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 196240, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 196657, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 196191, Russian Federation
  • GSK Investigational Site
    St.Petersburg, 194100, Russian Federation
  • GSK Investigational Site
    Tomsk, 634 050, Russian Federation
  • GSK Investigational Site
    Voronezh, 394036, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150003, Russian Federation
  • GSK Investigational Site
    Middelburg, Mpumalanga 1055, South Africa
  • GSK Investigational Site
    Bellville, 7530, South Africa
  • GSK Investigational Site
    Cape Town, 7500, South Africa
  • GSK Investigational Site
    Cape Town, 7700, South Africa
  • GSK Investigational Site
    Cape Town, 7708, South Africa
09

References and documents

Publications

  • Bareille P, Imber V, Crawford J, Majorek-Olechowska B, Karam-Absi Z, Stone S, Birk R. A multicenter randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of a 1-year regimen of orally inhaled fluticasone furoate 50 microg once daily on growth velocity in prepubertal, pediatric participants with well-controlled asthma. Pediatr Pulmonol. 2023 Dec;58(12):3487-3497. doi: 10.1002/ppul.26679. Epub 2023 Sep 20. PubMed 37728224 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Apr 2021, 44 months.

Results were first posted in Jan 2022, 8 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 44 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 7, 2016
StartActual
Jul 10, 2017
Primary completionActual
Apr 9, 2021
CompletionActual
Jun 4, 2021
Results first posted
Jan 4, 2022
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02889809
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Jul 10, 2017
Primary completion
Apr 9, 2021
Completion
Jun 4, 2021
Results posted
Jan 4, 2022
Last update
Jan 17, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion